{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:51:22Z","timestamp":1768315882001,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Obstetrics and Gynecology Kurume University"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ygyno.2018.07.014","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T01:46:40Z","timestamp":1532137600000},"page":"432-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-630X","authenticated-orcid":false,"given":"Shin","family":"Nishio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4132-6379","authenticated-orcid":false,"given":"Teruyuki","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Matsukuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsumu","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotake","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichiro","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimio","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.07.014_bb0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tjog.2015.09.010","article-title":"Incidence and lifetime risk of uterine corpus cancer in Taiwanese women from 1991 to 2010","volume":"56","author":"Lai","year":"2017","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.49.1.8","article-title":"Cancer statistics, 1999","volume":"49","author":"Landis","year":"1999","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.maturitas.2014.04.009","article-title":"Early recurrence of early stage endometrioid endometrial carcinoma: possible etiological pathways and management options","volume":"78","author":"Iavazzo","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.ygyno.2018.07.014_bb0025","first-page":"797","article-title":"Personalized care in uterine cancer","volume":"10","author":"Iglesias","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"24","author":"Randall","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy versus cisplatinbased combined chemotherapy in patients with intermediate- and high\u2013risk endometrial cancer: a Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0040","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer: results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.014_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0090-8258(02)00068-9","article-title":"Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Lincoln","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1006\/gyno.1999.5652","article-title":"Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group","volume":"75","author":"Moore","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0055","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study","volume":"20","author":"Muggia","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0060","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/gyno.2001.6491","article-title":"Evaluation of pyrazoloacridine (PZA) (NSC#366140) in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"84","author":"Plaxe","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/gyno.2002.6804","article-title":"Evaluation of topotecan in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"87","author":"Miller","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0070","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2006.03.043","article-title":"Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"103","author":"Fracasso","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/B:DRUG.0000026262.77502.31","article-title":"Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group","volume":"22","author":"Schilder","year":"2004","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2018.07.014_bb0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2008.06.013","article-title":"Phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"111","author":"Garcia","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2009.09.004","article-title":"A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group","volume":"115","author":"Miller","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0090","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2008.20.6995","article-title":"Phase II trial of Ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129P","volume":"27","author":"Dizon","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2010.11.027","article-title":"A phase II study of gemcitabine (GEMZAR, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"121","author":"Tait","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0100","first-page":"21","article-title":"CPT-11: an original spectrum of clinical activity","volume":"23","author":"Rothenberg","year":"1996","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00001813-200008000-00009","article-title":"In vitro sensistivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other anticancer drugs","volume":"11","author":"Hiramatsu","year":"2000","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2018.07.014_bb0110","first-page":"1353","article-title":"Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: a comparison with cisplatin","volume":"20","author":"Koshiyama","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0115","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1200\/JCO.2003.12.093","article-title":"Topotecan is an active in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93","volume":"21","author":"Wadler","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0120","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ygyno.2005.10.013","article-title":"The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer","volume":"100","author":"Matsumoto","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0125","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/jog.12062","article-title":"Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride\/nedaplatin therapy","volume":"29","author":"Takatori","year":"2013","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0130","first-page":"6921","article-title":"Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis","volume":"60","author":"Ando","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0135","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2005.03.0239","article-title":"Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin","volume":"24","author":"Han","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0140","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00280-013-2145-6","article-title":"Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer","volume":"71","author":"Cortejoso","year":"2013","journal-title":"Cancer Chemoter. Pharmacol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1479-5876-11-73","article-title":"A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer","volume":"11","author":"Shen","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ygyno.2018.07.014_bb0155","first-page":"290","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"84","author":"Eisehnauer","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.014_bb0160","first-page":"29","article-title":"Japanese ovarian trials: focus on irinotecan","volume":"5","author":"Sugiyama","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ygyno.2018.07.014_bb0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2003.02.091","article-title":"Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer","volume":"21","author":"Bodurka","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0170","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/gyno.1998.5129","article-title":"A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study","volume":"70","author":"Look","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0175","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a gynecologic oncology groups study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0180","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2013.09.021","article-title":"Applicability of the concept of \u201cplatinum sensitivity\u201d to recurrent endometrial cancer: the SGSG-012\/GOTIC-004\/Intergoup study","volume":"131","author":"Nagao","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0185","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.1997.15.2.625","article-title":"Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix","volume":"15","author":"Verschraegen","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0190","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.7754\/Clin.Lab.2017.170105","article-title":"UGT1A1 gene polymorphism predicts irinotecan-induced severe neutropenia and diarrhea in Chinese cancer patients","volume":"63","author":"Peng","year":"2017","journal-title":"Clin. Lab."},{"key":"10.1016\/j.ygyno.2018.07.014_bb0195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/1759-7714.12535","article-title":"Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer","volume":"9","author":"Fukuda","year":"2018","journal-title":"Thorac. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T10:56:16Z","timestamp":1534416976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818310783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0090825818310783"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}